Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue

Cancer Cytopathology

Volumn 123, Issue 1, 2015, Pages 30-39

  Gailey, Michael P ^a   Stence, Aaron A ^a   Jensen, Chris S ^a   Ma, Deqin ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

DNA extraction; fine needle aspirate; molecular oncology test; next generation sequencing; Sanger sequencing; single nucleotide primer extension assay

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; RAS PROTEIN; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PARAFFIN;

ADENOCARCINOMA; ADENOCARCINOMA OF UNKNOWN ORIGIN; ARTICLE; BRAF GENE; CANCER TEST; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; DNA EXTRACTION; EGFR GENE; FINE NEEDLE ASPIRATION BIOPSY; FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE PRIMER EXTENSION ASSAY; SUREPATH THIN LAYER PREPARATION; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TISSUE PREPARATION; TOUCH PREPARATION; TRANSITIONAL CELL CARCINOMA; CYTODIAGNOSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASMS; PATHOLOGY;

CYTODIAGNOSIS; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84925352314     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21476     Document Type: Article

References (15)

1. Kanagal-Shamanna R, Portier BP, Singh RR, et al. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014; 27: 314-327.
2. Karnes HE, Duncavage EJ, Bernadt CT,. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol. 2014; 122: 104-113.
3. Poller DN, Glaysher S,. BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. Cytopathology. 2014; 15: 155-159.
4. Bernacki KD, Betz BL, Weigelin HC, et al. Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study. Am J Clin Pathol. 2012; 138: 670-677.
5. Ferraz C, Rehfeld C, Krogdahl A, et al. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears. Thyroid. 2012; 22: 1025-1030.
6. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011; 136: 564-571.
7. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One. 2010; 5: e8802.
8. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
9. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
10. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94: 2092-2098.
11. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96: 3390-3397.
12. Nikiforov YE, Yip L, Nikiforova MN,. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res. 2013; 19: 2283-2288.
13. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol. 2010; 118: 17-23.
14. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010; 95: 1365-1369.
15. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013; 137: 828-860.